BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28474731)

  • 1. A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy.
    Santuario-Facio SK; Cardona-Huerta S; Perez-Paramo YX; Trevino V; Hernandez-Cabrera F; Rojas-Martinez A; Uscanga-Perales G; Martinez-Rodriguez JL; Martinez-Jacobo L; Padilla-Rivas G; Muñoz-Maldonado G; Gonzalez-Guerrero JF; Valero-Gomez J; Vazquez-Guerrero AL; Martinez-Rodriguez HG; Barboza-Quintana A; Barboza-Quintana O; Garza-Guajardo R; Ortiz-Lopez R
    Mol Med; 2017 Jun; 23():101-111. PubMed ID: 28474731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Zheng T; Pang Z; Zhao Z
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC.
    Tan R; Li H; Huang Z; Zhou Y; Tao M; Gao X; Xu Y
    Sci Rep; 2020 Feb; 10(1):3065. PubMed ID: 32080331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
    Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
    Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
    Fan CN; Ma L; Liu N
    J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.
    Qian J; Chen H; Ji X; Eisenberg R; Chakravarthy AB; Mayer IA; Massion PP
    Sci Rep; 2017 Apr; 7():45828. PubMed ID: 28387221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of FOXC1/FOXCUT/DANCR axis in triple negative breast cancer: a bioinformatics and experimental approach.
    Kamaliyan Z; Mirfakhraie R; Azizi-Tabesh G; Darbeheshti F; Omranipour R; Ahmadinejad N; Zokaei E; Yassaee VR
    Mol Biol Rep; 2022 Apr; 49(4):2821-2829. PubMed ID: 35066769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
    Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
    Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
    Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
    PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.
    Jiang YZ; Liu YR; Xu XE; Jin X; Hu X; Yu KD; Shao ZM
    Cancer Res; 2016 Apr; 76(8):2105-14. PubMed ID: 26921339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Pineda B; Diaz-Lagares A; Pérez-Fidalgo JA; Burgués O; González-Barrallo I; Crujeiras AB; Sandoval J; Esteller M; Lluch A; Eroles P
    Clin Epigenetics; 2019 Feb; 11(1):33. PubMed ID: 30786922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
    Angelini G; Marini C; Iacconi C; Mazzotta D; Moretti M; Picano E; Morganti R
    Clin Imaging; 2018; 49():12-16. PubMed ID: 29120811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
    Jovanović B; Sheng Q; Seitz RS; Lawrence KD; Morris SW; Thomas LR; Hout DR; Schweitzer BL; Guo Y; Pietenpol JA; Lehmann BD
    BMC Cancer; 2017 Apr; 17(1):241. PubMed ID: 28376728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
    Tang X; Thompson KJ; Kalari KR; Sinnwell JP; Suman VJ; Vedell PT; McLaughlin SA; Northfelt DW; Aspitia AM; Gray RJ; Carter JM; Weinshilboum R; Wang L; Boughey JC; Goetz MP
    Breast Cancer Res; 2023 May; 25(1):57. PubMed ID: 37226243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
    J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.